<DOC>
	<DOCNO>NCT02602652</DOCNO>
	<brief_summary>The objective study measure Geometric mean titer ( GMT ) Japanese Encephalitis neutralize antibody proportion seroprotection among child receive booster dose JE-CV first dose SA14-14-2 vaccine .</brief_summary>
	<brief_title>Immunogenicity JE-CV Booster Dose After Primary Vaccination With SA14-14-2 Vaccine</brief_title>
	<detailed_description>Study design : This open label clinical trial 50 child age 1-5 year , conduct King Chulalongkorn Memorial Hospital Thailand . The protocol approve Institutional Review Board Chulalongkorn University , study perform accordance Declaration Helsinki , International Conference Harmonization Good Clinical Practice , European Directive 2001/20/EC , write informed consent obtain parent legally acceptable representative enrolment . Vaccines : JE-CV manufacture Sanofi Pasteur Biologics Co. , USA. , reconstitute use 0.4 % sodium chloride diluent injection ; dose 0.5 ml contain 4.0-5.8 log10 plaque form unit virus Serology : JE neutralize antibody level assess use PRNT50 assay . The final end point neutralization titer inverse high serial dilution serum neutralize â‰¥ 50 % JE challenge virus . Testing performed Focus Diagnostics Inc. use JE-CV challenge virus . Statistical method : sample size calculate base historical data JE15 study , month 24 first dose JE-CV , GMT JE neutralize antibody 39.4 ( 95 % CI 33.7 46.0 ) increase 2242 ( 95 % CI 1913 , 2628 ) day 28 post JE-CV booster dose . On assumption child receive SA14-14-2 vaccine subsequently get one booster dose JE-CV 12-24 month later GMT least 1040 , 80 % power alpha 0.05 , data least 43 child need collect . When account 15 % child might loss follow-up get adequate blood sample , 50 child enrol . The per-protocol population use main immunogenicity analysis . For main parameter , 95 % confidence interval ( CIs ) point estimate calculate use normal approximation quantitative data exact binomial distribution proportion . The point estimate 95 % CI follow present group Geometric Mean ( GM ) neutralize antibody D0 D28 percentage subject neutralize antibody &gt; =10 D0 D28</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 Children age 1 &lt; 5 year day inclusion 2 . History receive 1 dose SA14142 vaccine 1224 month prior enrollment 3 . In good general health time inclusion 4 . Provision inform consent parent ( ) legal guardian ( ) 1 . Receipt blood blood product past 3 month . 2 . Acute febrile illness day vaccination . ( BT &gt; 38 C )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>geometric mean titer</keyword>
	<keyword>seroprotection</keyword>
	<keyword>live attenuate chimeric JE vaccine</keyword>
	<keyword>JE-CV</keyword>
	<keyword>SA14-14-2 vaccine</keyword>
</DOC>